CD133、TROP-2在非小细胞肺癌中的表达及相关性研究初探

The expression and correlation of CD133 and TROP-2 in NSCLC

目的:探讨肿瘤干细胞标志物CD133、人滋养层细胞表面抗原-2(trophoblast cell-surface antigens 2,TROP-2)在非小细胞肺癌(non-small cell lung cancer,NSCLC)中的表达及意义。方法:用免疫组化、免疫荧光法检测CD133、TROP-2在NSCLC中的表达,激光共聚焦显微镜观察其定位和共定位。结果:①CD133、TROP-2在NSCLC组织中的阳性表达率分别为30.00%和41.25%,均明显高于癌周正常肺组织及肺良性病变组织(P<0.01);②细胞分化程度越低,CD133表达阳性率越高(P=0.024);③CD133、TROP-2在有淋巴结转移组的阳性表达率高于无淋巴结转移组(P<0.05),TROP-2的阳性表达率随着TNM分期的升高而升高(P<0.05);④CD133、TROP-2在NSCLC中的表达具有密切相关性(P<0.001),且两种蛋白有共定位现象。结论:CD133、TROP-2的阳性表达均与NSCLC的侵袭、转移密切相关,初步证实二者在NSCLC组织中存在共定位关系,CD133联合TROP-2或许能成为NSCLC的肿瘤干细胞筛选标记物。

Objective：To investigate the expression and significance of cancer stem cell markers CD133 and TROP-2 in non-small cell lung carcinoma（NSCLC）. Methods：The expression of CD 133 and TROP-2 in NSCLC was detected by immunohistochemistry and double-labelling immunofluorescence. The location and the colocalization of the two proteins were observed under light microscope and confocal laser scanning microscope. Results： （1）The expression rate of CD133 and TROP-2 were 30.0% and 41.25% in 80 NSCLC tissues respectively,which were significantly higher than that in the tumor-adjacent normal tissues or benign lesion tissues（P 〈 0.01 ） ;（2）CD133-positive expression was significantly higher in poor differentiated tumor than that in the well differentiated tumor（P = 0.024） ; （3） Positive expression of CD133 and TROP-2 in the lymph node metastasis group was significantly higher than that in the non-lymph node metastasis group （P 〈 0.05）. The positive expression rate of TROP-2 increased with the increasing Tumor-Nodes- Metastasis （TNM） stage （P 〈 0.05）. （4）CD133 expression was correlated with TROP-2 expression （P 〈 0.001）. And there was collocation between the CD133 and TROP-2 proteins. Conclusion：The expression CD133 and TROP-2 was associated with the invasion and metastasis of NSCLC. Their colocalization in NSCLC was detected preliminarily. CD133 and TROP-2 may be used as two important markers in judging the cancer stem cell of NSCLC.